

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2570024

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.	10/01/2013
RECEIVING PARTY DATA	
Name:	NOVARTIS PHARMA AG
Street Address:	LICHSTRASSE, 35
City:	4056 BASEL
State/Country:	SWITZERLAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13799076
CORRESPONDENCE DATA	
Fax Number:	(857)300-4001
Phone:	857-300-4003
Email:	bostonpatent@lathropgage.com, ekarnas@lathropgage.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	BRIAN C. TRINQUE, PH.D., ESQ.
Address Line 1:	LATHROP & GAGE LLP
Address Line 2:	28 STATE STREET, 7TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	544250 (NVT-100)
NAME OF SUBMITTER:	BRIAN C. TRINQUE, PH.D., ESQ.
Signature:	/Brian C. Trinquet/
Date:	10/08/2013
Total Attachments: 3 source=Assignment_NIBR_to_NAG#page1.tif source=Assignment_NIBR_to_NAG#page2.tif source=Assignment_NIBR_to_NAG#page3.tif	

CH \$40.00 13799076

ASSIGNMENT

WHEREAS, **Novartis Institutes for Biomedical Research, Inc.** a corporation duly organized under the laws of the United States, and having its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States is the owner by assignment of certain applications identified as:

COMBINATION THERAPY

U.S. Application No.: 13/799,076, filed March 13, 2013

WHEREAS, **Novartis Pharma AG** a corporation duly organized under the laws of Switzerland, and having its principal place of business at Lichstrasse, 35, 4056 Basel, Switzerland is desirous of acquiring all rights, title and interests in and to said invention said applications, and in and to any and all Letters Patent which may be granted for or upon said invention and applications in the United States of America and all countries foreign thereto.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Novartis Institutes for Biomedical Research, Inc.** has sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said **Novartis Pharma AG** the full and exclusive right, title and interest, throughout the world, in, to and under the following:

- (a) said invention as fully set forth and described in the specification prepared,
and executed by us preparatory to obtaining Letters Patent of the United States therefor;
- (b) said applications;
- (c) any and all refilings, divisions, continuations and continuations-in-part of said application;

(d) any and all Letters Patent of the United States of America which may issue from said application, refilings, divisions, continuations and continuations-in-part;

(e) any and all reissues and reexaminations of said Letters Patent of the United States of America;

(f) any and all applications for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;

(g) any and all refilings, divisions and continuations of said foreign-filed applications;

(h) all claims, causes of action and damages for past infringement, if any, of said application;


(i) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed applications, refilings, divisions and continuations; and

(j) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

Novartis Institutes for Biomedical Research, Inc. further agree that upon request we will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to **Novartis Pharma AG** or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

ALL of the above shall be held and enjoyed by the said **Novartis Pharma AG** for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said Letters Patent may be granted, and do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.


Novartis Institutes of Biomedical Research, Inc.



Signature




Name




Title

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:


WITNESS




Signed At (City/State)



Name



Signature



Date